Anti Vascular Endothelial Growth Factor Agents in Corneal Neovascularization

Corneal neovascularisation is a potentially blinding condition, an established risk factor for rejection and results in loss of immune privilege. It may occur as a normal physiologic healing response to various stimuli or as an inappropriate local tissue response to primary insult arising due to an...

Full description

Saved in:
Bibliographic Details
Main Authors: Srivatsa Sehra, Reetika
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2011-07-01
Series:Delhi Journal of Ophthalmology
Subjects:
Online Access:https://journals.lww.com/10.4103/0972-0200.376568
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850143799830904832
author Srivatsa Sehra
Reetika
author_facet Srivatsa Sehra
Reetika
author_sort Srivatsa Sehra
collection DOAJ
description Corneal neovascularisation is a potentially blinding condition, an established risk factor for rejection and results in loss of immune privilege. It may occur as a normal physiologic healing response to various stimuli or as an inappropriate local tissue response to primary insult arising due to an imbalance between the angiogenic and antiangiogenic factors present in the normally avascular cornea. Medical and surgical treatment modalities have been described for the condition but there is no established treatment protocol. Anti vascular endothelial growth factor (Anti VEGF) agents are increasingly being used for the condition. In this article, we have presented the pathogenesis of corneal neovascularisation, role of VEGF and discussed the emerging use of anti VEGF agents as a treatment modality.
format Article
id doaj-art-e938ced906b34462b44062947de68d4c
institution OA Journals
issn 0972-0200
2454-2784
language English
publishDate 2011-07-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Delhi Journal of Ophthalmology
spelling doaj-art-e938ced906b34462b44062947de68d4c2025-08-20T02:28:33ZengWolters Kluwer Medknow PublicationsDelhi Journal of Ophthalmology0972-02002454-27842011-07-01221515410.4103/0972-0200.376568Anti Vascular Endothelial Growth Factor Agents in Corneal NeovascularizationSrivatsa SehraReetikaCorneal neovascularisation is a potentially blinding condition, an established risk factor for rejection and results in loss of immune privilege. It may occur as a normal physiologic healing response to various stimuli or as an inappropriate local tissue response to primary insult arising due to an imbalance between the angiogenic and antiangiogenic factors present in the normally avascular cornea. Medical and surgical treatment modalities have been described for the condition but there is no established treatment protocol. Anti vascular endothelial growth factor (Anti VEGF) agents are increasingly being used for the condition. In this article, we have presented the pathogenesis of corneal neovascularisation, role of VEGF and discussed the emerging use of anti VEGF agents as a treatment modality.https://journals.lww.com/10.4103/0972-0200.376568corneal neovascularizationvascular endothelial growth factorbevacizumab
spellingShingle Srivatsa Sehra
Reetika
Anti Vascular Endothelial Growth Factor Agents in Corneal Neovascularization
Delhi Journal of Ophthalmology
corneal neovascularization
vascular endothelial growth factor
bevacizumab
title Anti Vascular Endothelial Growth Factor Agents in Corneal Neovascularization
title_full Anti Vascular Endothelial Growth Factor Agents in Corneal Neovascularization
title_fullStr Anti Vascular Endothelial Growth Factor Agents in Corneal Neovascularization
title_full_unstemmed Anti Vascular Endothelial Growth Factor Agents in Corneal Neovascularization
title_short Anti Vascular Endothelial Growth Factor Agents in Corneal Neovascularization
title_sort anti vascular endothelial growth factor agents in corneal neovascularization
topic corneal neovascularization
vascular endothelial growth factor
bevacizumab
url https://journals.lww.com/10.4103/0972-0200.376568
work_keys_str_mv AT srivatsasehra antivascularendothelialgrowthfactoragentsincornealneovascularization
AT reetika antivascularendothelialgrowthfactoragentsincornealneovascularization